|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Páez D, Labonte MJ and Lenz HJ: Pancreatic
cancer: Medical management (novel chemotherapeutics). Gastroenterol
Clin North Am. 41:189–209. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hidalgo M, Cascinu S, Kleeff J, Labianca
R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL and Heinemann V:
Addressing the challenges of pancreatic cancer: Future directions
for improving outcomes. Pancreatology. 15:8–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Poruk KE, Firpo MA and Mulvihill SJ:
Screening for pancreatic cancer. Adv Surg. 48:115–136. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eser S, Schnieke A, Schneider G and Saur
D: Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer.
111:817–822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun C, Rosendahl AH, Andersson R, Wu D and
Wang X: The role of phosphatidylinositol 3-kinase signaling
pathways in pancreatic cancer. Pancreatology. 11:252–260. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dimitrova V and Arcaro A: Targeting the
PI3K/AKT/mTOR signaling pathway in medulloblastoma. Curr Mol Med.
15:82–93. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW,
Wang Z, Fan J, Dai Z and Zhou J: CXCR2/CXCL5 axis contributes to
epithelial-mesenchymal transition of HCC cells through activating
PI3K/AKT/GSK-3β/Snail signaling. Cancer Lett. 358:124–135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Falasca M, Selvaggi F, Buus R, Sulpizio S
and Edling CE: Targeting phosphoinositide 3-kinase pathways in
pancreatic cancer-from molecular signalling to clinical trials.
Anticancer Agents Med Chem. 11:455–463. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ji BC, Hsiao YP, Tsai CH, Chang SJ, Hsu
SC, Liu HC, Huang YP, Lien JC and Chung JG: Cantharidin impairs
cell migration and invasion of A375.S2 human melanoma cells by
suppressing MMP-2 and −9 through PI3K/NF-κB signaling pathways.
Anticancer Res. 35:729–738. 2015.PubMed/NCBI
|
|
11
|
Massimiani M, Vecchione L, Piccirilli D,
Spitalieri P, Amati F, Salvi S, Ferrazzani S, Stuhlmann H and
Campagnolo L: Epidermal growth factor-like domain 7 promotes
migration and invasion of human trophoblast cells through
activation of MAPK, PI3K and NOTCH signaling pathways. Mol Hum
Reprod. 21:435–451. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carnero A and Paramio JM: The
PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front Oncol.
4:2522014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu J, Li Z, Wang J, Chen H and Fang JY:
Combined PTEN mutation and protein expression associate with
overall and disease-free survival of glioblastoma patients. Transl
Oncol. 7:196–205. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hühns M, Salem T, Schneider B, Krohn M,
Linnebacher M and Prall F: PTEN mutation, loss of heterozygosity,
promoter methylation and expression in colorectal carcinoma: Two
hits on the gene? Oncol Rep. 31:2236–2244. 2014.PubMed/NCBI
|
|
15
|
Rosenfeldt H, Vazquez-Prado J and Gutkind
JS: P-REX2, a novel PI-3-kinase sensitive Rac exchange factor. FEBS
Lett. 572:167–171. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pandiella A and Montero JC: Molecular
pathways: P-Rex in cancer. Clin Cancer Res. 19:4564–4569. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo B, Liu L, Yao J, Ma R, Chang D, Li Z,
Song T and Huang C: miR-338-3p suppresses gastric cancer
progression through a PTEN-AKT axis by targeting P-REX2a. Mol
Cancer Res. 12:313–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Berger MF, Hodis E, Heffernan TP, Deribe
YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E,
Ghosh P, et al: Melanoma genome sequencing reveals frequent PREX2
mutations. Nature. 485:502–506. 2012.PubMed/NCBI
|
|
19
|
Lan X, Xiao F, Ding Q, Liu J, Liu J, Li J,
Zhang J and Tian DA: The effect of CXCL9 on the invasion ability of
hepatocellular carcinoma through up-regulation of PREX2. J Mol
Histol. 45:689–696. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen X, Pan M, Han L, Lu H, Hao X and Dong
Q: miR-338-3p suppresses neuroblastoma proliferation, invasion and
migration through targeting PREX2a. FEBS Lett. 587:3729–3737. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fine B, Hodakoski C, Koujak S, Su T, Saal
LH, Maurer M, Hopkins B, Keniry M, Sulis ML, Mense S, et al:
Activation of the PI3K pathway in cancer through inhibition of PTEN
by exchange factor P-REX2a. Science. 325:1261–1265. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao H, Wang L, Wei R, Xiu D, Tao M, Ke J,
Liu Y, Yang J and Hong T: Activation of glucagon-like peptide-1
receptor inhibits tumourigenicity and metastasis of human
pancreatic cancer cells via PI3K/AKT pathway. Diabetes Obes Metab.
16:850–860. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Missiaglia E, Dalai I, Barbi S, Beghelli
S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A,
delle Fave G, et al: Pancreatic endocrine tumors: Expression
profiling evidences a role for AKT-mTOR pathway. J Clin Oncol.
28:245–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
